Fig. 4
From: Selective increase in subtelomeric DNA methylation: an epigenetic biomarker for malignant glioma
The changes in methylation level (%) were quantitatively determined at each of the CpG sites in Chr. 21q (a) and Chr. XpYp (b). In both the chromosomes, we have observed significant increase in methylation level among glioma patients in comparison to the group of control patients. Methylation in glioma and control patients is presented with green and red colored box-plots, respectively